Fundraising FoxCatalio Capital Management — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+12 more
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla Ventures+13 more
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsDroia VenturesARCH Venture PartnersB Capital GroupB4 CapitalVida VenturesPolaris Partners
.jpeg){kind=logo}
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.